Alembic Pharmaceuticals Receives FDA Approval for Generic Valganciclovir Oral Solution

Alembic Pharmaceuticals Limited has secured final U.S. FDA approval for its 50 mg/mL valganciclovir oral solution, a generic version of Valcyte. This approval offers a more cost-effective treatment for CMV retinitis in AIDS patients and for preventing CMV disease in organ transplant recipients. This regulatory action is expected to increase generic medication availability and reduce prescription drug costs.